Condition
Major Depression Disorders
Total Trials
3
Recruiting
2
Active
2
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
33%
1 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
2Total
Not Applicable (1)
P 4 (1)
Trial Status
Recruiting2
Completed1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT07226011Not ApplicableRecruiting
Accelerated High-Dose tDCS for Depression
NCT07329673Recruiting
An Examination of the Performance of QbMobile in Differential Diagnosis Associated With ADHD Symptoms
NCT06664138Phase 4Completed
Comparison of Remimazolam and Etomidate As Induction Agents for Electroconvulsive Treatment
Showing all 3 trials